Pegfilgrastim - A health economic model to assess overall cost-effectiveness

EJHP Practice

Volumn 15, Issue 5, 2009, Pages 58-61

  Borget, Isabelle ^a   Di Palma, Mario ^a   Leonard, Robert ^b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; FEBRILE NEUTROPENIA; FRANCE; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; RISK REDUCTION; UNITED KINGDOM;

EID: 70450159652     PISSN: 17819989     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Lyman GH, Lyman CH, Agboola O. Risk models for predicting chemotherapy-induced neutropenia. Oncologist. 2005;10(6): 427-437
2. Kuderer NM, et al. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007;25(21):3158-3167
3. Kuderer NM, et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006; 106(10):2258-2266
4. Padilla G, Ropka ME. Quality of life and chemotherapy-induced neutropenia. Cancer Nurs. 2005;28(3):167-171
5. Chirivella I, et al. Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients. Breast Cancer Res Treat. 2009; 114(3):479-484
6. Pinto L, et al. Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials. Curr Med Res Opin. 2007; 23(9): 2283-2295
7. Smith TJ, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006; 24(19):3187-3205
8. Aapro MS, et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapyinduced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer. 2006;42(15):2433-2453
9. NCCN Clinical Practice Guidelines in Oncology Myeloid Growth Factors. V.1.2009. [cited 2009 September 15]. Available from: www.nccn.org
10. Neupogen Summary of Product Characteristics (SmPC). Electronic Medicines Compendium (EMC). [cited 2009 September 15]. Available from: www.emc.medicines.org.uk
11. Green MD, et al. Arandomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol. 2003;14(1):29-35.
12. Holmes FA, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol. 2002;20(3):727-731
13. Siena S, et al. A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily Filgrastim in patients with stage II-IV breast cancer. Oncol Rep. 2003;10(3):715-724
14. von Minckwitz G, et al. Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. Ann Oncol. 2008;19(2):292-298
15. Heckinger EA. Cost minimization analysis of filgrastim (G-CSF) versus pegfilgrastim (peg-G-CSF) for stage II-IV breast cancer patients receiving chemotherapy: assessments based on third-party and societal perspectives. Proc Am Soc Clin Oncol. 2003;22 (abstract 2116).
16. Weycker D, Hackett J, Edelsberg JS, et al. Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization? Ann Pharmacother. 2006; 40(3):402-407
17. Bonadonna G, et al. 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ. 2005;330(7485):217.
18. Liu Z, et al. The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UK. Applied Health Economics and Health Policy. 2009: In press.
19. Leonard RC, et al. Impact of neutropenia on delivering planned adjuvant chemotherapy: UK audit of primary breast cancer patients. Br J Cancer. 2003;89(11):2062-2068
20. Bogillot O, et al. Comparaison médico-économique du pegfilgrastim et du filgrastim. Santé Décision Management. 2008;11:183-200.